Risk Intelligence
55 / 100
Exit Review
How strong and defensively sound is the company?
Weaker than most covered companies on this measure.
ABT · NYSE
Sector unavailable · Industry unavailable
$101.95
-1.36%
Close on Sep 11, 2026
Updated 6/30/2026
Long-term research evidence only. No price targets, no trading signals, no recommendations.
Investment Report Card
Sector unavailable · Data confidence good
27 / 100
Rank #625 of 1,152 qualified companies
Top 91% · Not Currently Suggested
55 / 100
Exit Review
How strong and defensively sound is the company?
Weaker than most covered companies on this measure.
54 / 100
Not Scored
Does the business have the characteristics needed to create value over many years?
Weaker than most covered companies on this measure.
34 / 100
Not Scored
Is the underlying business getting stronger or weaker?
Weaker than most covered companies on this measure.
61 / 100
Positive disclosed activity
What are important owners actually doing?
Around the middle of the covered universe.
65 / 100
Attractive
Is today's price reasonable?
Around the middle of the covered universe — and valuation is researched separately from the Suggested Investment Score.
62 / 100
Favorable Capital Returns
How effectively does the company reward shareholders?
Around the middle of the covered universe — and capital returns are researched separately from the Suggested Investment Score.
ABBOTT LABORATORIES scores 54 on Long-Term Potential (D+), described by the research model as not scored. This describes business characteristics only — it is not a forecast of future returns.
Disclosed ownership evidence reads 61 (C): Positive disclosed activity. 11 tracked managers disclosed a position in the latest reporting period. Ownership filings are historical disclosures, not signals.
ABBOTT LABORATORIES reads 65 out of 100 on Valuation Intelligence, recorded as Attractive. The stock currently trades below most of its own recent valuation history. This describes the price being paid relative to the company's financials — it is not a forecast and not a fair value. Valuation Intelligence is a research model and contributes nothing to the Suggested Investment Score or the daily ranking.
ABBOTT LABORATORIES reads 62 out of 100 on Capital Returns Intelligence (Favorable Capital Returns), reflecting a dividend that has grown about 9.4% a year and a share count falling about 0.6% a year. Capital Returns Intelligence is a research model and contributes nothing to the Suggested Investment Score or the daily ranking.
No meaningful recorded changes in the stored history.
Risk Intelligence is a core model, Long-Term Potential, Fundamental Momentum, Valuation Intelligence and Capital Returns Intelligence are research models, and Ownership Intelligence is supplemental descriptive evidence. Valuation Intelligence and Capital Returns Intelligence each contribute 0% to the Suggested Investment Score. Nothing here is a recommendation.
Compare ABT with other companiesAppears in
Membership means the company satisfied a published rule on the latest research build. It is not a recommendation.
About a minute to read
Written from stored research readings only. No hype. No trading signals. Just better evidence.
ABBOTT LABORATORIES (ABT) scores 27 out of 100 and ranks #625 of 1,152 qualified companies today. That places it in the top 91% of ranked companies. The stored tier for that score is not currently suggested.
Risk Intelligence reads 55 out of 100 (D+), recorded as exit review. Weaker than most covered companies on this measure.
Long-Term Potential reads 54 out of 100 (D+), recorded as not scored. Weaker than most covered companies on this measure.
Fundamental Momentum reads 34 out of 100 (F), recorded as not scored. Weaker than most covered companies on this measure.
Ownership Intelligence reads 61 out of 100 (C), recorded as positive disclosed activity. Around the middle of the covered universe.
Valuation currently appears favourable: Valuation Intelligence reads 65 out of 100 (C+), recorded as Attractive. ABBOTT LABORATORIES reads 65 out of 100 on Valuation Intelligence, recorded as Attractive. The stock currently trades below most of its own recent valuation history. This describes the price being paid relative to the company's financials — it is not a forecast and not a fair value. Valuation Intelligence is a research model and contributes nothing to the Suggested Investment Score or the daily ranking.
Capital Returns Intelligence reads 62 out of 100 (C), recorded as Favorable Capital Returns. ABBOTT LABORATORIES reads 62 out of 100 on Capital Returns Intelligence (Favorable Capital Returns), reflecting a dividend that has grown about 9.4% a year and a share count falling about 0.6% a year. Capital Returns Intelligence is a research model and contributes nothing to the Suggested Investment Score or the daily ranking.
This company is in Exit Review under the existing quality rules, which is the most serious caution the research records can carry.
No individual layer reaches the strongest band today. Risk Intelligence and Long-Term Potential and Fundamental Momentum remain the main area to watch. Separately from the score, valuation reads attractive at today's price.
Composite discovery model
Suggested Investment Score
27 / 100
A 0–100 composite discovery score combining Risk Intelligence, Long-Term Potential, Fundamental Momentum, and Ownership Intelligence. It helps rank qualified companies for further research and does not predict future returns.
30% contribution
30% contribution
20% contribution
20% contribution
61 / 100 · Moderately Positive · 20% of the Suggested Investment Score
Coverage: Good
50% of Ownership Intelligence · 10% of the total score
Tracked professional-manager activity is moderately positive.
20% of Ownership Intelligence · 4% of the total score
Broad institutional evidence from resolved filings is strong.
15% of Ownership Intelligence · 3% of the total score
No discretionary insider transactions are stored for this company, so this evidence is unavailable rather than neutral.
15% of Ownership Intelligence · 3% of the total score
No qualifying major-holder filings are stored, so this evidence is unavailable rather than neutral.
Ownership Intelligence summarizes publicly disclosed activity among professional investment managers, broader institutions, company insiders, and significant strategic owners. It adds context to investment research but is not a validated predictor of future performance. Ownership information is publicly reported with a delay; the latest applicable reporting period is 2026-06-30, publicly disclosed 9/11/2026. Congressional activity is unavailable pending legal review and contributes nothing to this reading.
No component ranks in the top quartile of the qualified universe.
Risk Intelligence is less favourable
Defensive characteristics rank below the middle of the qualified universe.
Long-term potential is mid-pack
Long-Term Potential ranks below the qualified median. This remains a research model.
Fundamental Momentum is softer
Reported business trends rank below the qualified median.
Ownership evidence is not uniformly supportive
The combined disclosed ownership evidence ranks below the qualified median.
Ownership evidence disagrees
Different owner groups point in different directions, so the combined reading is best read as mixed rather than uniformly favourable.
COMPOSITE DISCOVERY MODEL — RESEARCH STAGE · Data coverage Excellent. Rankings are recalculated daily using the latest available information. Individual components may update at different frequencies based on when new financial and ownership data becomes available.
Researched separately
Valuation Intelligence 65 · Attractive
Valuation Intelligence is currently researched separately and does not affect the Suggested Investment Score or daily ranking.
Researched separately
Capital Returns Intelligence 62 · Favorable Capital Returns
Capital Returns Intelligence is researched separately and contributes 0% to the Suggested Investment Score, the daily rank or any ranking event.
Score explanation
Four research areas carry fixed weights. Each area is compared against every other eligible company, then weighted. The four contributions below add to 27.0 of the stored score (27.0).
Risk Intelligence
30% of the score · contributes 4.2 points
How strong and defensively sound is the company?
Stands at the 14 percentile of eligible companies · stored reading 55 · 15% of this company’s total score
How financially sturdy the company has been when conditions turned against it.
Risk Intelligence reads stored balance-sheet strength, historical downside behaviour and the company's price-risk grouping. A stronger reading describes past resilience; it does not protect against future losses.
Full methodologyLong-Term Potential
30% of the score · contributes 14.5 points
Does the business have the characteristics needed to create value over many years?
Stands at the 48 percentile of eligible companies · stored reading 54 · 54% of this company’s total score
Whether the business has the durable characteristics long-term owners look for.
Long-Term Potential reads durability characteristics such as profitability consistency, cash generation and reinvestment capability over multiple reported periods.
Full methodologyFundamental Momentum
20% of the score · contributes 3.6 points
Is the underlying business getting stronger or weaker?
Stands at the 18 percentile of eligible companies · stored reading 34 · 13% of this company’s total score
Whether the reported business results have been getting stronger or weaker.
Fundamental Momentum compares recent reported fundamentals with the company's own earlier periods, so improvement or deterioration is measured against its history rather than against a forecast.
Full methodologyOwnership Intelligence
20% of the score · contributes 4.8 points
What are important owners actually doing?
Stands at the 24 percentile of eligible companies · stored reading 61 · 18% of this company’s total score
What large reporting owners have actually been doing with their positions.
Ownership Intelligence reads public ownership filings: how many tracked reporting owners hold the company, and whether they were adding, holding, reducing or exiting in the latest disclosed period.
Full methodologyNo research area currently stands in the stronger half of eligible companies.
Additional research — not currently included in the primary Suggested Investment Score.
Stored snapshots only
Research-score history available since September 2026.
Stored research history does not yet cover a full 30 days comparison for this company.
A change is reported as meaningful at 8 score points, 5 rank places, or any change of research classification. Nothing here is a recommendation to buy or sell.
Plain-English definitions, with the formula and the limitations of each measure.
Fifth research lens · outside the score
Valuation Intelligence
Valuation Intelligence is currently researched separately and does not affect the Suggested Investment Score or daily ranking.
Attractive
78
Very Attractive
Is this company expensive or inexpensive compared with its own history?
—
Not Available
How expensive is this stock compared with similar companies?
No comparable cohort of at least eight companies with the same usable ratios.
53
Reasonable
How much financial output does an investor receive relative to the price paid?
62
Attractive
Does the company's growth help justify the valuation investors are paying?
ABBOTT LABORATORIES reads 65 out of 100 on Valuation Intelligence, recorded as Attractive. The stock currently trades below most of its own recent valuation history. This describes the price being paid relative to the company's financials — it is not a forecast and not a fair value.
Price data through September 11, 2026 · Financial data through the quarter ended June 30, 2026
Stored readings only. The dashed line is this company's own median for the selected measure.
Only one stored valuation reading exists so far, so there is nothing to chart yet. Valuation history builds forward from activation rather than being reconstructed.
Current P/E 32.5x · own median 36.2x
Valuation is inherently uncertain. A stock that appears inexpensive can continue falling, and a stock that appears expensive can continue rising. Valuation Intelligence provides context about the price investors are paying — it does not predict short-term market movements, and it never produces a fair value, a price target or a buy or sell range. Model VALUATION_INTELLIGENCE_V1.
Sixth research lens · outside the score
Capital Returns Intelligence
Capital Returns Intelligence is researched separately and contributes 0% to the Suggested Investment Score, the daily rank or any ranking event.
Favorable Capital Returns
87
Exceptional Capital Returns
Dividend reliability
48
Moderate Capital Returns
Do buybacks actually reduce shares?
49
Moderate Capital Returns
Is your ownership share protected?
62
Favorable Capital Returns
Can the cash flow support it?
60
Favorable Capital Returns
Cash returned versus company value
ABBOTT LABORATORIES reads 62 out of 100 on Capital Returns Intelligence (Favorable Capital Returns), reflecting a dividend that has grown about 9.4% a year and a share count falling about 0.6% a year.
How returned cash was used
Dividends $4.26B · net repurchases $1.64B · total returned $5.90B · 75% of free cash flow
Price data through September 11, 2026 · Financial data through the quarter ended June 30, 2026
Stored readings only. History builds forward from activation rather than being reconstructed.
Only one stored reading exists for this measure so far, so there is nothing to chart yet.
A very high dividend yield may reflect a falling share price or an unsustainable payout. Capital Returns Intelligence emphasizes consistency and sustainability rather than simply rewarding the highest yield.
Announced or gross buyback spending does not always mean shareholders are gaining ownership. Companies can simultaneously issue shares through employee compensation or acquisitions. Suggested Investments therefore considers actual share-count changes alongside repurchase spending.
Capital Returns Intelligence describes how a company returns capital to shareholders. It is not a measure of stock-price performance, it does not predict future returns, and a strong reading is never a recommendation to buy. Dividends and repurchases can be reduced or stopped at any time. Model CAPITAL_RETURNS_INTELLIGENCE_V1, contributing 0% to the Suggested Investment Score.
Stored daily snapshots only
| Today | #625 | Score 27 |
|---|---|---|
| 30 days ago | Not ranked | No stored score |
| 90 days ago | Not ranked | No stored score |
| First suggested | Not yet suggested | |
| Highest rank | #625 | |
In the company’s own words
Abbott Laboratories is an Illinois corporation, incorporated in 1900. Abbott’s* principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products.
On November 19, 2025, Abbott entered into a definitive agreement to acquire Exact Sciences Corporation (Exact Sciences), which is expected to enable Abbott to enter the cancer diagnostics market. The acquisition is subject to customary closing conditions, including the approval of Exact Sciences shareholders and obtaining the required regulatory clearances.
Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
These products include a broad line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States in emerging markets. These products are generally sold directly to wholesalers, distributors, government agencies, healthcare facilities, pharmacies, and independent retailers from Abbott-owned distribution centers or public warehouses, depending on the market served. Certain products are co-marketed or co-promoted with, or licensed from, other companies.
Quoted from the business section of this company’s 10-K filed February 20, 2026. Read the filing
Four distinct intelligence areas
55
Fundamentally Qualified
+29.2 vs Jun 30, 2026
Business Quality qualification score from the locked IA Defensive Research Core. Price Risk stays a separate category and is never blended in.
As of Sep 11, 2026
54
Ordinary Compounder
No prior period to compare
Durable business economics and reinvestment characteristics. Independent external validation is pending.
As of Sep 11, 2026
34
Deteriorating
No prior period to compare
Direction and breadth of change in underlying business fundamentals. Not a price-momentum signal.
As of Sep 11, 2026
50
Mid range
0 vs Jun 30, 2026
11 tracked managers disclosed a position for this period.
As of Sep 11, 2026
Company intelligence
Each area is measured and reported separately. No combined score exists.
ABT intelligence history from 2023-09-30 to 2026-09-11. Risk Intelligence 54.7 on 2026-09-11, up 29.2 from 25.5 on 2026-06-30. Long-Term Potential 53.8 on 2026-09-11. Fundamental Momentum 33.5 on 2026-09-11. Elite Investor Activity 50 on 2026-09-11, unchanged 0 from 50 on 2026-06-30. Each area is reported separately and is never combined into a single score.
Risk Intelligence 54.7 as of Sep 11, 2026 (+29.2 vs prior period) · Production core
Long-Term Potential 53.8 as of Sep 11, 2026 · Research model
Fundamental Momentum 33.5 as of Sep 11, 2026 · Research model
Elite Investor Activity 50 as of Sep 11, 2026 (0 vs prior period) · Supplemental
Share price
Closing prices adjusted for splits and dividends, through Sep 11, 2026. Past prices do not indicate future results.
Last stored close $101.95 · -21.4% over the selected range · 52 sessions shown
Balanced evidence
Risk and uncertainty
Public filings · descriptive only
Reporting holders
55
New holders
36
Increasing
10
Reducing
5
Exiting
1
Coverage
Excellent
Positive disclosed activity · Report period 2023-09-30 · Public 12/27/2023
| Manager | Change | Portfolio weight | Rank | Disclosed |
|---|
Insufficient high-confidence manager coverage.
Objective stored changes
IA Defensive weakened
Business Quality qualification score moved from 33.6 to 25.5.
Exit Review triggered
Business Quality fell below the Exit Review threshold. Exit Review is a prompt for review, never an automatic sell.
Tracked managers exited positions
3 tracked managers no longer disclosed a position for the reporting period ending 2026-03-31.
Elite Investor Consensus strengthened
Disclosed agreement among tracked managers moved from 23 to 50 for the reporting period ending 2025-12-31.
Elite Investor Consensus weakened
Disclosed agreement among tracked managers moved from 47 to 23 for the reporting period ending 2025-09-30.
Elite Investor Consensus strengthened
Disclosed agreement among tracked managers moved from 36 to 47 for the reporting period ending 2025-03-31.
Tracked managers initiated positions
2 tracked managers first disclosed a position for the reporting period ending 2025-03-31.
Elite Investor Consensus weakened
Disclosed agreement among tracked managers moved from 96 to 36 for the reporting period ending 2024-12-31.
Tracked managers initiated positions
12 tracked managers first disclosed a position for the reporting period ending 2024-09-30.
No high-confidence public ownership events are available.
General research only. Not personalized advice. Public filings may be delayed, amended, incomplete, or reflect positions that have changed since the reporting date.